Precision medicine and personalized breast cancer: combination pertuzumab therapy
Kerry Reynolds, Sasmit Sarangi, Aditya Bardia, Don S Dizon Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA Abstract: Trastuzumab (Herceptin), a monoclonal antibody directed against the human epidermal growth-factor receptor 2 (HER2), is the poster child for anti...
Saved in:
Main Authors: | Reynolds K (Author), Sarangi S (Author), Bardia A (Author), Dizon DS (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2014-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pertuzumab Increases 17-AAG-Induced Degradation of ErbB2, and This Effect Is Further Increased by Combining Pertuzumab with Trastuzumab
by: Juliana Bentes Hughes, et al.
Published: (2012) -
Xeloda Oral, Trastuzumab, and Pertuzumab Combined Drug Therapy Reduced Cervical Lymphadenopathy and Dermal Involvement in Patient With Recurrent Breast Cancer: Case Report
by: Victor Manuel Saure Sarría, et al.
Published: (2020) -
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
by: Lamond NW, et al.
Published: (2014) -
Value of UGT2B7-161 Single Nucleotide Polymorphism in Predicting the Risk of Cardiotoxicity in HER-2 Positive Breast Cancer Patients Who Underwent Pertuzumab Combined with Trastuzumab Therapy by PSL
by: Li J, et al.
Published: (2022) -
FROM PERSONALIZED TO PRECISION MEDICINE
by: K. V. Raskina, et al.
Published: (2017)